Search results
Researchers identify a key metabolic gene as target for improved cancer immunotherapy
Medical Xpress· 1 day agoInhibiting this gene through pharmacologic or genetic intervention led to better T-cell infiltration, increasing effectiveness of immunotherapy in a type of pancreatic cancer called PDAC. The ...
7 Stocks That Could Safely 10X by 2030
InvestorPlace· 1 day agoHere are seven possible 10x stocks worth looking into. Cloudflare (NYSE:NET) provides vital internet security and performance services to a huge portion...
Study reveals role of neutrophil lipid transfer in lung cancer transition
Medical Xpress· 2 days agoPhenotypic plasticity is a cancer hallmark, and lung adeno-to-squamous transition (AST) triggered by...
Olivia Munn admits she wasn’t planning on having children before her ‘surprise’ pregnancy
The Independent via Yahoo News· 3 days agoThe announcement came just two months after he filed for divorce from his wife of six years, Anna...
Bristol Myers Squibb’s Breyanzi shows promise in B-cell malignancy clinical trials
Clinical Trials Arena via Yahoo Finance· 3 days agoThe findings include results from the Phase III TRANSFORM trial of Breyanzi as a second-line...
Escaping the cycle: Tahoe Forest’s fight against addiction through community-based rehabilitation...
Sierra Sun· 9 hours agoAmid the ongoing crisis of accidental opioid overdoses, understanding and utilizing local resources for substance use disorder rehabilitation has never been more critical. “Many patients have ...
What's Going On With Bio-Path Stock? - Bio-Path Hldgs (NASDAQ:BPTH)
Benzinga· 4 days agoThe company presented data on Saturday which showed prexigebersen to be well-tolerated and has...
Beyond Air shares hold Buy rating on positive data from a Phase 1a trial By Investing.com
Investing.com· 4 days agoBeyond Cancer, a subsidiary of Beyond Air, showcased these findings at the American Society of...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 hours agoNEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody
First witness called in Hunter Biden’s gun trial
WJZY via Yahoo News· 3 days agoDefense opening statements Hunter Biden’s defense team’s argument hinges on two claims: that Hunter Biden didn’t knowingly break the law because he was...
